FD-TACT malaria treatment trial launches patient recruitment in Rwanda
13 Oct 2025
A Phase 3 pivotal trial, co-led by IDDO/WWARN scientist Dr Mehul Dhorda, has begun to evaluate a novel fixed-dose triple artemisinin-based combination treatment (FD-TACT) for uncomplicated Plasmodium falciparum malaria.
i
Credit Mehul Dhorda
Researchers at MORU, funded by Japan’s Global Health Innovative Technology Fund (GHIT), are testing a single-formulation treatment combining artemether-lumefantrine and amodiaquine (ALAQ) developed by Fosun Pharma. The FD-TACT trial aims to provide an easy-to-administer treatment for adults, adolescents, and children over 6 months, to address the growing threat of resistance to artemisinins, the global frontline treatment for malaria.
Dr Mehul Dhorda, Coordinator and Co-Principal Investigator of the FD-TACT trial at MORU, said: “Triple ACTs could be key to ensuring that artemisinin resistance does not derail malaria control and elimination efforts in Africa.”